bioTheranostics, Genomic Health report data

bioTheranostics (San Diego, Calif.) said data from tissue samples from 166 estrogen receptor-positive breast cancer patients showed that the company's Theros Breast Cancer Index (BCI) reduced the number of patients classified as having an intermediate risk of recurrence by 2.5-fold vs. Oncotype Dx from Genomic Health (18% vs. 45%, respectively). Theros BCI classified 69% and 13% of patients as low and high risk, respectively, vs. 48% and 7% for Oncotype Dx. Risk stratifications between the two CLIA tests were significantly correlated (p<0.001). bioTheranostics is wholly owned by bioMerieux (Euronext:BIM). Separately, Genomic Health (NASDAQ:GHDX) said data from tumor tissue samples from 1,231 evaluable European post-menopausal women with hormone receptor-positive breast cancer treated with an aromatase inhibitor showed that Oncotype DX had a significantly greater prognostic value vs. Adjuvant! Online in both node-negative and node-positive patients (p<0.001 and p=0.003, respectively). Adjuvant! Online is a web-based tool to estimate the risk of negative outcome with or without systemic adjuvant therapy based on clinical information such as patient age, tumor size, nodal involvement and histologic grade. Oncotype DX also significantly predicted time to recurrence in node-negative patients (p<0.001). ...